Caladrius Biosciences Inc (NASDAQ:CLBS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, May 3rd.
According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “
Separately, HC Wainwright set a $7.00 target price on Caladrius Biosciences and gave the company a “buy” rating in a research report on Monday, March 20th.
Shares of Caladrius Biosciences (NASDAQ:CLBS) traded down 4.48% during trading on Wednesday, reaching $4.90. The company’s stock had a trading volume of 37,189 shares. Caladrius Biosciences has a 52-week low of $2.65 and a 52-week high of $7.79. The stock’s 50 day moving average price is $4.81 and its 200-day moving average price is $4.34.
Caladrius Biosciences (NASDAQ:CLBS) last announced its quarterly earnings data on Thursday, May 18th. The biotechnology company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by $0.40. Caladrius Biosciences had a negative return on equity of 270.38% and a negative net margin of 183.36%. The firm had revenue of $7.92 million during the quarter, compared to the consensus estimate of $9.50 million. On average, equities analysts anticipate that Caladrius Biosciences will post ($3.14) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.chaffeybreeze.com/2017/05/19/caladrius-biosciences-inc-clbs-lowered-to-sell-at-zacks-investment-research-updated.html.
A number of hedge funds have recently made changes to their positions in CLBS. Eagle Global Advisors LLC bought a new stake in shares of Caladrius Biosciences during the third quarter valued at about $127,000. KCG Holdings Inc. raised its stake in shares of Caladrius Biosciences by 74.6% in the first quarter. KCG Holdings Inc. now owns 36,291 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 15,501 shares in the last quarter. Knoll Capital Management LP acquired a new stake in shares of Caladrius Biosciences during the third quarter valued at approximately $266,000. Renaissance Technologies LLC raised its stake in shares of Caladrius Biosciences by 149.2% in the fourth quarter. Renaissance Technologies LLC now owns 72,652 shares of the biotechnology company’s stock valued at $206,000 after buying an additional 43,500 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Caladrius Biosciences by 39.3% in the first quarter. Vanguard Group Inc. now owns 151,217 shares of the biotechnology company’s stock valued at $761,000 after buying an additional 42,644 shares in the last quarter. 19.42% of the stock is currently owned by institutional investors and hedge funds.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc, formerly NeoStem, Inc, through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Caladrius Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.